

# **Global Neglected Tropical Diseases Drugs And Vaccines Market Size study, by Product (Drugs, Vaccines), by Disease (Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya), and Regional Forecasts 2022-2032**

<https://marketpublishers.com/r/G0C8256203E8EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G0C8256203E8EN

## **Abstracts**

Global Neglected Tropical Diseases (NTDs) Drugs and Vaccines Market is valued at approximately USD 2.07 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.00% during the forecast period 2024 to 2032. Addressing the global health gap, the NTDs drugs and vaccines market emerges as a crucial force in combating diseases long sidelined due to socioeconomic inequalities and infrastructural shortcomings. Affecting more than a billion people globally, these infections—such as leishmaniasis, dengue, lymphatic filariasis, and chikungunya—are prevalent in low-income, tropical, and subtropical regions. Governments, philanthropic bodies, and global health agencies are amplifying efforts to eradicate these preventable illnesses through collaborative R&D pipelines and equitable distribution models for effective pharmaceutical interventions.

The resurgence of research interest in neglected tropical diseases is being propelled by a combination of public-private partnerships, WHO-backed roadmaps, and emerging innovations in vaccine technology. Biopharmaceutical enterprises are increasingly leveraging mRNA platforms, adjuvant combinations, and recombinant protein technologies to develop next-gen vaccines for these diseases. Meanwhile, drug development efforts are benefiting from AI-driven molecule screening and improved genomic insights into pathogens, enabling targeted therapeutics with fewer side effects. However, the demand is not just about discovery—it's about scalable access. Initiatives

such as the Drugs for Neglected Diseases initiative (DNDi) and GAVI-led immunization drives underscore the urgency of creating affordable, shelf-stable formulations suited to fragile health ecosystems.

Despite momentum, the market still contends with structural and logistical hurdles. Fragmented supply chains, limited cold chain infrastructure, regulatory complexities, and insufficient return on investment have traditionally constrained commercial interest in this sector. Moreover, the ever-evolving nature of tropical disease outbreaks, coupled with emerging resistance to antiparasitic drugs, introduces additional uncertainty. Nevertheless, stakeholder collaboration is intensifying, and multi-sectoral alliances are now integrating diagnostics, therapeutics, and vaccines under comprehensive disease eradication strategies. The rising global focus on pandemic preparedness has also placed neglected diseases under the broader spotlight of health security, incentivizing long-term funding and cross-border cooperation.

From a product perspective, both vaccines and therapeutics are expected to maintain strong demand, with vaccines gaining traction as preventive medicine in outbreak-prone regions. Drug interventions remain essential for chronic or recurring infections like leishmaniasis and filariasis. Market players are adopting modular production techniques, heat-stable packaging, and novel oral administration routes to suit low-resource settings. The growing convergence of field-based clinical trial networks and digital health technologies is enabling real-time epidemiological surveillance, data-driven resource allocation, and faster regulatory approvals across endemic geographies.

Regionally, Latin America and Sub-Saharan Africa remain the most impacted and are thus central to the market's growth trajectory. Brazil, Kenya, Nigeria, and India represent key hotspots where disease burden intersects with public health innovation and donor-funded intervention frameworks. Asia Pacific—particularly India and Southeast Asia—is accelerating vaccine R&D with the support of biotech clusters and WHO collaborations. North America and Europe, though lower in endemicity, continue to play pivotal roles as innovation hubs and funding powerhouses, driving the global supply chain of NTD medicines and vaccines. Multilateral efforts like the London Declaration and UN Sustainable Development Goals are expected to sustain long-term momentum and funding alignment.

**Major market player included in this report are:**

GlaxoSmithKline plc

Novartis AG

Johnson & Johnson

Sanofi S.A.

Merck & Co., Inc.

Pfizer Inc.

Bayer AG

Cipla Limited

Eisai Co., Ltd.

Cadila Pharmaceuticals

Serum Institute of India Pvt. Ltd.

BioE (Biological E. Limited)

Bharat Biotech International Limited

PATH

MedinCell SA

**The detailed segments and sub-segment of the market are explained below:**

By Product

Drugs

Vaccines

## By Disease

Lymphatic Filariasis

Echinococcosis

Leishmaniasis

Dracunculiasis

Dengue

Chikungunya

## By Region:

### North America

U.S.

Canada

### Europe

UK

Germany

France

Spain

Italy

Rest of Europe

## Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

## Latin America

Brazil

Mexico

Rest of Latin America

## Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

## **Years considered for the study are as follows:**

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

### **Key Takeaways:**

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

### **Companies Mentioned**

GlaxoSmithKline plc

Novartis AG

Johnson & Johnson

Sanofi S.A.

Merck & Co., Inc.

Pfizer Inc.

Bayer AG

Cipla Limited

Eisai Co., Ltd.

Cadila Pharmaceuticals

Serum Institute of India Pvt. Ltd.

BioE (Biological E. Limited)

Bharat Biotech International Limited

PATH

MedinCell SA

## Contents

### **CHAPTER 1. GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET EXECUTIVE SUMMARY**

- 1.1. Global Neglected Tropical Diseases Drugs And Vaccines Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Product
  - 1.3.2. By Disease
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Availability
    - 2.3.3.2. Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Market Competition
    - 2.3.3.5. Economic Viability (Healthcare Systems)
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Regulatory Frameworks & Funding
    - 2.3.4.2. Technological Advancements
    - 2.3.4.3. Environmental & Epidemiological Considerations
    - 2.3.4.4. Patient & Community Awareness
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

### **CHAPTER 3. GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND**

*Global Neglected Tropical Diseases Drugs And Vaccines Market Size study, by Product (Drugs, Vaccines), by Dise...*



## **VACCINES MARKET DYNAMICS**

### **3.1. Market Drivers**

- 3.1.1. Increased Public-Private Partnerships and Funding
- 3.1.2. Advances in mRNA and Recombinant Vaccine Platforms
- 3.1.3. Growing Emphasis on Disease Eradication Roadmaps

### **3.2. Market Challenges**

- 3.2.1. Fragmented Supply Chains and Cold-Chain Limitations
- 3.2.2. Regulatory Complexities Across Endemic Regions
- 3.2.3. Limited Commercial Incentives for Low-ROI Indications

### **3.3. Market Opportunities**

- 3.3.1. Heat-Stable and Oral Formulation Innovations
- 3.3.2. Integration of Diagnostics with Therapeutic Campaigns
- 3.3.3. Expansion of Field-Based Clinical Trial Networks

## **CHAPTER 4. GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET INDUSTRY ANALYSIS**

### **4.1. Porter's 5 Forces Model**

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Forces
- 4.1.7. Porter's 5 Forces Impact Analysis

### **4.2. PESTEL Analysis**

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

### **4.3. Top Investment Opportunities**

### **4.4. Top Winning Strategies**

### **4.5. Disruptive Trends**

### **4.6. Industry Expert Perspective**

### **4.7. Analyst Recommendation & Conclusion**

## **CHAPTER 5. GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE & FORECASTS BY PRODUCT (2022–2032)**

5.1. Segment Dashboard

5.2. Market: Drugs vs. Vaccines Revenue Trend Analysis, 2022 & 2032 (USD Billion)

## **CHAPTER 6. GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE & FORECASTS BY DISEASE (2022–2032)**

6.1. Segment Dashboard

6.2. Market: Lymphatic Filariasis; Echinococcosis; Leishmaniasis; Dracunculiasis; Dengue; Chikungunya Revenue Trend Analysis, 2022 & 2032 (USD Billion)

## **CHAPTER 7. GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE & FORECASTS BY REGION (2022–2032)**

7.1. North America Market

7.1.1. U.S. Market

7.1.1.1. Product Breakdown & Forecasts, 2022–2032

7.1.1.2. Disease Breakdown & Forecasts, 2022–2032

7.1.2. Canada Market

7.2. Europe Market

7.2.1. UK

7.2.2. Germany

7.2.3. France

7.2.4. Spain

7.2.5. Italy

7.2.6. Rest of Europe

7.3. Asia Pacific Market

7.3.1. China

7.3.2. India

7.3.3. Japan

7.3.4. Australia

7.3.5. South Korea

7.3.6. Rest of Asia Pacific

7.4. Latin America Market

7.4.1. Brazil

7.4.2. Mexico

7.4.3. Rest of Latin America

## 7.5. Middle East & Africa Market

7.5.1. Saudi Arabia

7.5.2. South Africa

7.5.3. Rest of Middle East & Africa

## **CHAPTER 8. COMPETITIVE INTELLIGENCE**

### 8.1. Key Company SWOT Analysis

8.1.1. GlaxoSmithKline plc

8.1.2. Novartis AG

8.1.3. Johnson & Johnson

### 8.2. Top Market Strategies

### 8.3. Company Profiles

8.3.1. GlaxoSmithKline plc

8.3.1.1. Key Information

8.3.1.2. Overview

8.3.1.3. Financial (Subject to Data Availability)

8.3.1.4. Product Summary

8.3.1.5. Market Strategies

8.3.2. Sanofi S.A.

8.3.3. Merck & Co., Inc.

8.3.4. Pfizer Inc.

8.3.5. Bayer AG

8.3.6. Cipla Limited

8.3.7. Eisai Co., Ltd.

8.3.8. Cadila Pharmaceuticals

8.3.9. Serum Institute of India Pvt. Ltd.

8.3.10. Biological E. Limited

8.3.11. Bharat Biotech International Limited

8.3.12. PATH

8.3.13. MedinCell SA

## **CHAPTER 9. RESEARCH PROCESS**

### 9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing  
9.2. Research Attributes

## List Of Tables

### LIST OF TABLES

TABLE 1. Global NTDs Drugs & Vaccines market, report scope
TABLE 2. Market estimates & forecasts by Region 2022–2032 (USD Billion)
TABLE 3. Estimates & forecasts by Product 2022–2032 (USD Billion)
TABLE 4. Estimates & forecasts by Disease 2022–2032 (USD Billion)
TABLE 5. North America market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 6. U.S. market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 7. Canada market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 8. Europe market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 9. UK market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 10. Germany market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 11. Asia Pacific market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 12. India market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 13. Latin America market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 14. Brazil market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 15. Middle East & Africa market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 16. Saudi Arabia market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 17. South Africa market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 18. Global competitive landscape analysis, 2023
TABLE 19. Historical vs. forecast comparison, 2022–2032 (USD Billion)
TABLE 20. Key donor funding trends, 2022–2032

## List Of Figures

### LIST OF FIGURES

- FIG 1. Research methodology
- FIG 2. Market estimation techniques
- FIG 3. Size estimates & forecast methods
- FIG 4. Key trends 2023
- FIG 5. Growth prospects 2022–2032
- FIG 6. Porter's 5 Forces model
- FIG 7. PESTEL analysis
- FIG 8. Value chain analysis
- FIG 9. Market by Product, 2022 & 2032 (USD Billion)
- FIG 10. Market by Disease, 2022 & 2032 (USD Billion)
- FIG 11. Market by Region, 2022 & 2032 (USD Billion)
- FIG 12. North America market, 2022 & 2032 (USD Billion)
- FIG 13. Europe market, 2022 & 2032 (USD Billion)
- FIG 14. Asia Pacific market, 2022 & 2032 (USD Billion)
- FIG 15. Latin America market, 2022 & 2032 (USD Billion)
- FIG 16. Middle East & Africa market, 2022 & 2032 (USD Billion)
- FIG 17. Company market share analysis (2023)
- FIG 18. Challenges and opportunities framework
- FIG 19. Vaccine versus drug adoption curve
- FIG 20. Donor investment landscape overview

## I would like to order

Product name: Global Neglected Tropical Diseases Drugs And Vaccines Market Size study, by Product (Drugs, Vaccines), by Disease (Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G0C8256203E8EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0C8256203E8EN.html>